Synthesis and In vitro Antimicrobial Activity of Novel 2-(4-(Substituted-carboxamido)benzyl / phenyl)benzothiazoles by Serap Yilmaz et al.
 
* Author to whom correspondence should be addressed. (E-mail: iyildiz@pharmacy.ankara.edu.tr) 
CROATICA CHEMICA ACTA 
CCACAA, ISSN 0011-1643, e-ISSN 1334-417X 
Croat. Chem. Acta 86 (2) (2013) 223–231.  
http://dx.doi.org/10.5562/cca2064 
Original Scientific Article 
Synthesis and In vitro Antimicrobial Activity of Novel  
2-(4-(Substituted-carboxamido)benzyl / phenyl)benzothiazoles 
Serap Yilmaz,a Ismail Yalcin,a Fatma Kaynak-Onurdag,b Selda Ozgen,b 
Ilkay Yildiz,a,* and Esin Akia 
aAnkara University, Faculty of Pharmacy, Department of Pharmaceutical Chemistry, 06100, Tandoğan, Ankara, Turkey 
bGazi University, Faculty of Pharmacy, Department of Pharmaceutical Microbiology, 06330, Etiler, Ankara, Turkey 
RECEIVED FEBRUARY 12, 2012; REVISED JUNE 9, 2013; ACCEPTED JUNE 20, 2013 
 
Abstract. A new series of 2-[4-(4-substitutedbenzamido / phenylacetamido / phenylpropionamido) benzyl 
/ phenyl]benzothiazole derivatives (6a−6w) were synthesized and evaluated for antibacterial and antifun-
gal activities against Staphylococcus aureus, Bacillus subtilis, Klebsiella pneumoniae, Pseudomonas 
aeruginosa, Escherichia coli with their drug-resistant isolates and a yeast Candida albicans. Microbiolog-
ical results indicated that the compounds possessed a broad spectrum of activity against the tested micro-
organisms at MIC values between 200 and 6.25 µg/ml. Compounds 6e and 6j exhibited the greatest activi-
ty with MIC values of 6.25 µg/ml against Pseudomonas aeruginosa, and Staphylococcus aureus isolate, 
respectively.(doi: 10.5562/cca2064) 
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INTRODUCTION 
Bacterial resistance to antibacterial agents or antibiotics 
is of grave concern in the medical community, as many 
species of bacteria have evolved resistance to certain 
antibiotics and synthetic agents. Therefore, there could 
be a rapidly growing global crisis in the clinical man-
agement of life-threatening infectious diseases caused 
by multidrug-resistant strains of the Gram-positive 
pathogens like Streptococcus, Enterococcus, and 
Staphylococcus, and Gram-negative pathogens like 
Escherichia, Salmonella, and certain Pseudomonas 
strains. Especially the emergence of multidrug-resistant 
strains of Gram-positive bacterial pathogens such as 
methicillin-resistant Staphylococcus aureus and Sta-
phylococcus epidermis and vancomycin-resistant En-
terococcus is an alarming problem of ever increasing 
significance.1–4 To meet this crisis successfully, many 
researchers across the globe are working to unearth 
new compounds which can selectively attack novel 
targets in microorganisms. Hence, the development of 
novel, potent, and unique antibacterial agents is the 
preeminent way to overcome bacterial resistance and 
develop effective therapies.5 
The compounds possess benzothiazole nucleus in 
their structure are involved in research aimed at evaluat-
ing new chemotherapeutically active agents: such as 
antimicrobial6–9 a topical carbonic anhydrase inhibitor,10 
a cyclooxygenase inhibitor,11 antitubercular,12,13 anti-
nematode,14 a dual inhibitor of thromboxane A2 
synthetase and 5-lipoxygenase15, a selective and re-
versible inhibitor of monoamine oxidase type A (MAO-
A),16 antiallergic,17 multi-drug resistance cancer cell 
activities with inhibiting activity on eukaryotic topoi-
somerase II enzyme in cell-free system18–20 and anti-
tumor agents.21–23 
Currently, a new series of benzothiazoles have 
been synthesized as antitumor agents and showed potent 
inhibitory activity against human breast cancer cell lines 
in vitro and in vivo.21 Among them, lysyl-amide of 2-(4-
amino-3-methylphenyl)-5-fluorobenzothiazole (Formula 
1) had been selected for phase 1 clinical evaluation.22 
In the last years, we reported the synthesis of sev-
eral 2-substitutedbenzothiazole derivatives as the anti-
Formula 1. 
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microbial agents7,8 as seen in Formula 2. According to 
these studies the compounds were found to have inhibi-
tory effect with MIC value of 3.12–50 µg/ml against 
some of Gram-positive, Gram-negative bacteria and 
Candida albicans as yeast. Among the tested com-
pounds, 2-(phenoxymethyl)benzothiazole was found the 
most active derivative at a MIC value of 3.12 µg/ml 
against the tested S. aureus.8 Moreover, the same com-
pound was found very potent as an eukaryotic topoiso-
merase II inhibitor exhibiting a better inhibitor activity 
than reference drug18–20 etoposide. 
Currently, we reported the synthesis and the anti-
microbial activity of 2-[4-(4-substituted-benzami-
do/phenylacetamido)phenyl]benzothiazole derivatives 
(7a–7k).24 In continuation to our ongoing research work 
on new 2-(4-carboxamido-benzyl / phenyl)benzothi-
azole derivatives, herein, we described the synthesis and 
in vitro antimicrobial activity of novel 2-[4-(4-substitu-
tedbenzamido / phenylacetamido / 3-phenylpropiona-
mido) benzyl / phenyl]benzothiazoles (6a−6w) (Formu-
la 3) against different Gram positive (Staphylococcus 
aureus, Bacillus subtilis) and Gram-negative (Klebsiella 
pneumoniae, Pseudomonas aeruginosa, Escherichia 
coli) bacteria with their drug-resistant isolates as well as 
the yeast C. albicans in comparison with several control 





The chemicals were purchased from the commercial 
venders and were used without purification. The reac-
tions were monitored and the purity of the products was 
checked by thin layer chromatography (TLC). Silicagel 
HF254 chromatoplates (0.3 mm) were used for TLC and 
the solvent systems were n-hexan:ethyl acetate (2:1) for 
2-(4-aminobenzyl/phenyl)benzothiazole (3) and chloro-
form:methanol (20:1) for compounds 6a−6w. Melting 
points were taken on a Buchi SMP 20 capillary appa-
ratus and are uncorrected. IR spectra were recorded by 
FT/IR-420 in KBr discs. 1H NMR spectra were obtained 
with a Varian Mercury 400 High Performance Digital 
FT-NMR-400 MHz spectrometer in d6-chloroform, 
tetramethylsilane (TMS) was used as an internal stand-
ard. Elemental analyses were carried out with CHNS-
932 (LECO) apparatus. The results (C, H, N) were with-
in ±0.4 % of the calculated values. Mass analysis was 
obtained by Waters 2695 Alliance ZQ Micromass LC-
MS working with ESI apparatus. 
 
General Procedure for the Synthesis of 2-(4-
aminobenzyl/phenyl)benzothiazole (3) 
2-(4-aminobenzyl/phenyl)benzothiazole (3) were pre-
pared by heating 1 mmol o-aminothiophenol (1) with 1 
mmol p-aminobenzoic acid / p-aminophenylacetic acid 
(2) in 2.4 g polyphosphoric acid and stirring for 4 h 
(Scheme 1). After then the residue was poured into ice-
water mixture and neutralized with excess of 10 % NaOH 
solution. The precipitate was boiled with activated char-
coal in ethanol and then, filtered and recrystallized in 
ethanol (m.p.(3a) = 155−157 ºC, m.p.(3b) = 93−94 ºC).23,25 
 
General procedure for the synthesis of compounds 
(6a–6w)  
The result products, 2-[4-(4-substitutedbenzamido/phe-
nylacetamido/3-phenyl propionamido)benzyl/phenyl]-




Scheme 1. Synthesis of 2-(4-aminobenzyl / phenyl)benzothiazoles. 
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heating thionyl chloride (0.3 ml) and appropriate car-
boxylic acid (4) (1 mmol) in benzene (0.5 ml) at 80 ºC 
for 3h, and then excess thionyl chloride was removed in 
vacuo (Scheme 2). The residue was dissolved in ether (1 
ml) and solution added during 1h to a stired, ice-cold 
mixture of 2-(4-aminobenzyl/phenyl)benzothiazole (1 
mmol), sodium bicarbonate (2 mmol), diethylether (1 
ml) and water (1 ml).26 The mixture was kept stirred 
overnight at room temperature and then filtered. After 
the precipitate was washed with water, 2N HCl and 
water. Ethanol was used for recrystallization and crys-
tals are dried in vacuo. 
 
2-[4-(benzamido)phenyl]benzothiazole (6a)23 
Yield: 52 %; m.p. = 222–224 ºC; IR v/cm−1: 3366, 2924, 
1658 (Amid I), 1599, 1531(Amid II), 1510, 1481, 1435 
(Amid III), 967–626, 730–626; 1H NMR (400 MHz, 
CDCl3) δ/ppm: 7.389 (t, J = 7.6 Hz, J = 7.6 Hz, 1H), 
7.480–7.547 (m, 3H), 7.587 (d, J = 7.2 Hz, 1H), 7.823 
(d, J’=8 Hz, 2H), 7.899–7.918 (m, 3H), 7.960 (s, 1H), 
8.064 (d, J = 7.6 Hz, 1H), 8.125 (d, J = 8.8 Hz, 2H); 
ESI (+) m/e: 331.33 (M++H)(%100); anal. found: C 
72.94, H 4.03, N 8.90, S 9.80; calcd. for C20H14N2OS · 
0.01 HCl: C 72.94, H 4.24, N 8.48, S 9.68. 
 
2-[4-(4-sec-butoxybenzamido)phenyl]benzothiazole (6b) 
Yield: 54 %: m.p. = 211–213 ºC; IR v/cm−1: 3318, 2968, 
2928, 1649 (Amid I), 1604, 1518 (Amid II), 1502, 1480, 
1435 (Amid III), 1251, 1032, 966–628, 727–628; 1H 
NMR (400 MHz, CDCl3) δ/ppm: 0.996 (t, J = 7,6 Hz, J 
= 7.6 Hz, 3H), 1.336 (d, J = 6.4 Hz, 3H), 1.579–1.817 
(m, 2H), 4.382–4.428 (m, 1H), 6.962 (d, J = 8,8 Hz, 
2H), 7.380 (t, J = 7.2 Hz, J = 7.2 Hz, 1H), 7.490 (t, J = 
8 Hz, J = 8.4 Hz, 1H), 7.799 (d, J = 9.2 Hz, 2H), 7.848 
(d, J = 8.8 Hz, 2H), 7.900 (d, J = 8 Hz, 1H), 7.927 (s, 
1H), 8.054 (d, J = 8.4 Hz, 1H), 8.099 (d, J = 8.4 Hz, 
2H); ESI (+) m/e: 403.40 (M++H)(%100); anal. found: 
C 71.31, H 5.50, N 7.08, S 8.13; calcd. for 
C24H22N2O2S: C 71.62, H 5.51, N 6.96, S 7.97.  
2-[4-(phenylacetamido)phenyl]benzothiazole (6c) 
Yield: 15 %; m.p. = 203–205 ºC; IR v/cm−1: 3305, 3054, 
1660 (Amid I), 1600, 1545 (Amid II), 1504, 1482, 1434 
(Amid III), 979–621, 728–621; 1H NMR (400 MHz, 
CDCl3) δ/ppm: 3.778 (s, 2H), 7.323–7.496 (m, 8H), 
7.573 (d, J = 8.4 Hz, 2H), 7.880 (d, J = 8 Hz, 1H), 
7.994−8.042 (m, 3H); ESI (+) m/e: 345.36 
(M++H)(%100); anal. found: C 72.37, H 5.02, N 8.47, S 
9.32; calcd. for C21H16N2OS · 0.15 H2O: C 72.65, H 
4.73, N 8.07, S 9.23. 
 
2-[4-(4-nitrophenylacetamido)phenyl]benzothiazole (6d) 
Yield: 27 %; m.p. = 250–252 ºC; IR v/cm−1: 3296, 1665 
(Amid I), 1612–1591, 1539 (Amid II), 1521, 1481, 1434 
(Amid III), 1350, 966–618, 726–618; 1H NMR 
(400MHz, DMSO-d6) δ/ppm: 3.928 (s, 2H), 7.442 (t,  
J = 6.8 Hz, J = 8 Hz, 1H), 7.535 (t, J = 7.2 Hz, J = 8 
Hz, 1H), 7.651 (d, J = 8.4 Hz, 2H), 7.828 (d, J = 8.8 
 
Scheme 2. General synthetic pathway of compounds 6a–6w. 
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Hz, 2H), 8.029 (d, J = 8 Hz, 1H), 8.067 (d, J = 8.4 Hz, 
2H), 8.128 (d, J = 8 Hz, 1H), 8.228 (d, J = 8.4 Hz, 2H), 
10.472 (s, 1H); ESI (+) m/e: 390.35 (M++H)(%100); 
anal. found: C 58.54, H 3.70, N 9.85, S 7.64; calcd. for 




Yield: 74 %; m.p. = 215–217 ºC; IR v/cm−1: 3314, 3027, 
1658 (Amid I), 1598, 1533 (Amid II),1506, 1480, 1434 
(Amid III), 965–631, 728–620; 1H NMR (400 MHz, 
CDCl3) δ/ppm: 2.705 (t, J = 7.6 Hz, J = 7.6 Hz, 2H), 
3.078 (t, J = 8 Hz, J = 7.2 Hz, 2H), 7.208–7.339 (m, 
5H), 7.375 (t, J = 7.6 Hz, J = 7.6 Hz, 1H), 7.483 (t, J = 
8 Hz, J = 7.2 Hz, 1H), 7.584 (d, J = 8.4 Hz, 2H), 7.890 
(d, J = 7.6 Hz, 1H), 8.020–8.050 (m, 3H); ESI (+) m/e: 
357.36 (M++H)(%100); anal. found: C 72.77, H 4.56, N 
7.86, S 9.08; calcd. for C22H18N2OS · 0.18 HCl: C 




Yield: 59 %; m.p. = 223–225 ºC. IR v/cm−1: 3281, 3031, 
2990, 2933, 2831, 1651 (Amid I), 1609–1584, 1532 
(Amid II), 1511, 1480, 1434 (Amid III), 1245, 1031, 
967–621, 730–621; 1H NMR (400 MHz, CDCl3) δ/ppm: 
2.674 (t, J = 7.6 Hz, J = 7.2 Hz, 2H), 3.023 (t, J = 7.2 
Hz, J = 7.6 Hz, 2H), 3.794 (s, 3H), 6.858 (d, J = 8.4 Hz, 
2H), 7.128 (s, 1H), 7.173 (d, J = 8.8 Hz, 2H), 7.374 (t, J 
= 7.2 Hz, J = 8 Hz, 1H), 7.484 (t, J = 8 Hz, J = 7.6 Hz, 
1H), 7.587 (d, J = 8.4 Hz, 2H), 7.893 (d, J = 7.6 Hz, 
1H), 8.025–8.053 (m, 3H); ESI (+) m/e: 389.40 
(M++H)(%100); anal. found: C 68.67, H 4.78, N 7.08, S 
8.11; calcd. for C23H20N2O2S · 0.4 HCl: C 68.58, H 
5.06, N 6.95, S 7.95. 
 
2-[4-(benzamido)benzyl]benzothiazole (6g) 
Yield: 69 %; m.p. = 197–199 ºC; IR v/cm−1: 3307, 3113, 
3054, 2911, 1647(Amid I), 1601–1577, 1532 (Amid II), 
1507, 1493, 1438 (Amid III), 974–605, 733–605. 1H 
NMR (400 MHz, CDCl3) δ/ppm: 4.425 (s, 2H), 7.323–
7.379 (m, 3H), 7.483–7.497 (m, 3H), 7.548 (t, J = 7.2 
Hz, J = 7.6 Hz, 1H), 7.641 (d, J = 8 Hz, 2H), 7.801 (d, 
J = 8 Hz, 1H), 7.848–7.889 (m, 3H), 7.995 (d, J = 8.4 
Hz, 1H). ESI (+) m/e: 345.32 (M++H)(%100); anal. 
found: C 73.69, H 4.32, N 8.53, S 9.46; calcd. for 
C21H16N2OS: C 73.23, H 4.68, N 8.13, S 9.31.  
2-[4-(4-fluorobenzamido)benzyl]benzothiazole (6h) 
Yield: 50 %; m.p. = 205–207 ºC; IR v/cm−1: 3289, 1650 
(Amid I), 1603, 1537 (Amid II), 1509, 1455, 1426 
(Amid III), 1229, 942–618, 733–618; 1H NMR (400 
MHz, CDCl3) δ/ppm: 4.431 (s, 2H), 7.160 (t, J = 8.4 
Hz, J = 8.8 Hz, 2H), 7.331–7.386 (m, 3H), 7.462 (t, J = 
8.4 Hz, J = 7.6 Hz, 1H), 7.619 (d, J = 8.4 Hz, 2H), 
7.805 (d, J = 7.6 Hz, 2H), 7.859–7.895 (m, 2H), 7.997 
(d, J = 8.4 Hz, 1H); ESI (+) m/e: 363.34 
(M++H)(%100); anal. found: C 66.63, H 3.83, N 7.77, S 
8.62; calcd. for C21H15FN2OS · 0.5 HCl: C 66.31, H 
4.07, N 7.37, S 8.42. 
 
2-[4-(4-chlorobenzamido)benzyl]benzothiazole (6i) 
Yield: 64; m.p. = 203–205 ºC; IR v/cm−1: 3351, 1653 
(Amid I), 1598, 1530 (Amid II), 1509, 1485, 1427 
(Amid III), 1093, 943–625, 726–625. 1H NMR (400 
MHz, CDCl3) δ/ppm: 4.426 (s, 2H), 7.330–7.379 (m, 
3H), 7.434–7.525 (m, 3H), 7.619 (d, J = 8 Hz, 2H), 
7.798 (d, J = 8.8 Hz, 2H), 7.881 (s, 1H), 7.996 (d, J = 
8.4 Hz, 1H), 8.076 (d, J = 8.4 Hz, 1H); ESI (+) m/e: 
381.29 (M++H+2)(%49), 379.28 (M++H)(%100); anal. 
found: C 66.28, H 3.98, N 7.57, S 8.08; calcd. for 
C21H15ClN2OS: C 66.57, H 3.99, N 7.39, S 8.46.  
2-[4-(4-bromobenzamido)benzyl]benzothiazole (6j) 
Yield: 45; m.p. = 180–182 ºC; IR v/cm−1: 3347, 
1653(Amid I), 1597, 1529 (Amid II), 1508, 1482, 
1427(Amid III), 1067, 942–623, 727–623. 1H NMR 
(400 MHz, CDCl3) δ/ppm: 4.430 (s, 2H), 7.328–7.386 
(m, 3H), 7.462 (t, J = 8 Hz, J = 8.4 Hz, 1H), 7.607–
6.628 (m, 4H), 7.727 (d, J = 8.4 Hz, 2H), 7.792–7.821 
(m, 2H), 7.995 (d, J = 8.4 Hz, 1H); ESI (+) m/e: 425.20 
(M++2)(%95), 423.09(M+)(%97), 423.29 (M+)(%100); 
anal. found: C 58.89, H 3.60, N 7.09, S 7.55; calcd. for 




Yield 19 %; m.p. = 204–206 ºC. IR v/cm−1: 3302, 1656 
(Amid I), 1597, 1528 (Amid II), 1512, 1455, 1436 
(Amid III), 1347, 932–622, 724–622. 1H NMR (400 
MHz, DMSO-d6) δ/ppm: 4.469 (s, 2H), 7.384–7.431 (m, 
3H), 7.498 (t, J = 8 Hz, J = 8.4 Hz, 1H), 7.790 (d, J = 
8.8 Hz, 2H), 7.969 (d, J = 7.6 Hz, 1H), 8.025 (d, J = 8.4 
Hz, 1H), 8.197 (d, J = 8.4, 2H), 8.383 (d, J = 9.2 Hz, 
2H), 10.633 (s, 1H); ESI (+) m/e: 390.33 
(M++H)(%100); anal. found: C 63.96, H 3.95, N 10.67, 
S 8.18; calcd. for C21H15N3O3S · 0.2 H2O: C 64.18, H 
3.92, N 10.69, S 8.15. 
 
2-[4-(4-ethylbenzamido)benzyl]benzothiazole (6l) 
Yield: 54 %; m.p. = 177–179 ºC. IR v/cm−1: 3306, 3102, 
3059, 3035, 2961, 2924, 1651 (Amid I), 1608–1596, 
1530 (Amid II), 1512, 1455, 1437 (Amid III), 970–616, 
731–616. 1H NMR (400 MHz, CDCl3) δ/ppm: 1.267 (t, 
J = 7.6 Hz, J = 7.6 Hz, 3H), 2.720 (q, 2H), 4.431 (s, 
2H), 7.302–7.384 (m, 5H), 7.460 (t, J = 8.4 Hz, J = 8.4 
Hz, 1H), 7.639 (d, J = 8.4 Hz, 2H), 7.778–7.811 (m, 
4H), 7.998 (d, J = 8.4 Hz, 1H); ESI (+) m/e: 373.35 
(M++H)(%100); anal. found: C 74.20, H 5.30, N 7.79, S 




Yield: 38 %; m.p. = 156–158 ºC. IR v/cm−1: 3280, 3061, 
2965, 2867, 1646 (Amid I), 1608–1597, 1532 (Amid II), 
1515, 1455, 1438 (Amid III), 966–601, 725–601; 1H 
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NMR (400 MHz, CDCl3) δ/ppm: 1.328 (s, 9H), 4.399 
(s, 2H), 7.314–7.349 (m, 3H), 7.424–7.463 (m, 3H), 
7.635 (d, J = 8.8 Hz 2H), 7.775–7.797 (m, 3H), 7.985 
(d, J = 8 Hz, 1H), 8.030 (s, 1H); ESI (+) m/e: 401.38 
(M++H)(%100); anal. found: C 75.06, H 5.71, N 7.26, S 




Yield: 34 m.p. = 154–156 ºC. IR v/cm−1: 3332, 2972, 
1644 (Amid I), 1597–1575, 1536 (Amid II), 1506, 1455, 
1436 (Amid III), 1254, 1029, 997–636, 729–636. 1H 
NMR (400 MHz, CDCl3) δ/ppm: 0.980 (t, J = 7.2 Hz, J 
= 7.6 Hz, 3H), 1.315 (d, J = 6.4 Hz, 3H), 1.609–1.799 
(m, 2H), 4.353–4.399 (m, 1H), 4.413 (s, 1H), 6.921 (d, J 
= 8.8 Hz, 2H), 7.320–7.355 (m, 3H), 7.452 (t, J = 8 Hz, 
J = 8.4 Hz, 1H), 7.622 (d, J = 8.4 Hz, 2H), 7.785–7.823 
(m, 3H), 7.877 (s, 1H), 7.992 (d, J = 8 Hz, 1H); ESI (+) 
m/e: 417.35 (M++H)(%100); anal. found: C 72.36, H 
5.58, N 7.08, S 7.70; calcd. for C25H24N2O2S: C 72.09, 
H 5.81, N 6.72, S 7.70. 
 
2-[4-(phenylacetamido)benzyl]benzothiazole (6o) 
Yield: 60 %; m.p. = 196–198 ºC; IR v/cm−1: 3277, 3059, 
1656 (Amid I), 1597, 1535 (Amid II), 1507, 1452, 1433 
(Amid III), 1235, 979–624, 729–624. 1H NMR (400 
MHz, CDCl3) δ/ppm: 3.734 (s, 2H), 4.372 (s, 2H), 7.169 
(s, 1H), 7.273 (d, J = 8.4 Hz, 2H), 7.315–7.466 (m, 9H), 
7.778 (d, J = 8 Hz, 1H), 7.973 (d, J = 8 Hz, 1H); ESI 
(+) m/e: 359.34(M++H)(%100); anal. found: C 73.77, H 
5.09, N 8.15, S 9.09; calcd. for C22H18N2OS: C 73.71, H 




Yield: 30 %; m.p. = 180–182 ºC. IR v/cm−1: 3261, 3052, 
1653 (Amid I), 1597, 1538 (Amid II), 1507, 1453, 1433 
(Amid III), 1225, 950–619, 728–619; 1H NMR (400 
MHz, CDCl3) δ/ppm: 3.677 (s, 2H), 4.366 (s, 2H), 7.059 
(t, J = 8.4 Hz, J = 8.8 Hz, 2H), 7.254–7.346 (m, 5H), 
7.404–7.460 (m, 3H), 7.773 (d, J = 7.6 Hz, 1H), 7.964 
(d, J = 8 Hz, 1H); ESI (+) m/e: 377.30 (M++H)(%100); 
anal. found: C 69.71, H 4.54, N 7.76, S 8.37; calcd. for 





Yield: 55 %; m.p. = 198–200 ºC; IR v/cm−1: 3295, 3052, 
2923, 1662 (Amid I), 1598, 1537 (Amid II), 1509, 1453, 
1437 (Amid III), 1093, 967–639, 731–639. 1H NMR 
(400 MHz, CDCl3) δ/ppm: 3.701 (s, 2H), 4.386 (s, 2H), 
7.099 (s, 1H), 7.265–7.376 (m, 7H), 7.417–7.473 (m, 
3H), 7.787 (d, J = 8.4 Hz, 1H), 7.979 (d, J = 8 Hz, 1H); 
ESI (+) m/e: 393.30(M++H)(%100), 395.34 
(M++H+2)(%43); anal. found: C 67.13, H 4.07, N 7.66, 
S 8.37; calcd. for C22H17ClN2OS: C 67.25, H 4.36, N 
7.13, S 8.16. 
2-[4-(4-bromophenylacetamido)benzyl]benzothiazole 
(6r) 
Yield: 58 %; m.p. = 206–208 ºC; IR v/cm−1: 3292, 3039, 
1663 (Amid I), 1598, 1534 (Amid II), 1509, 1455, 1434 
(Amid III), 1070, 973–627, 729–627; 1H NMR (400 
MHz, CDCl3) δ/ppm: 3.658 (s, 2H), 4.371 (s, 2H), 7.192 
(d, J = 8 Hz, 2H), 7.278 (d, J = 8.8 Hz, 2H), 7.329 (t, J 
= 7.2 Hz, J = 8 Hz, 1H), 7.406–7.459 (m, 3H), 7.496 (d, 
J = 8.4 Hz, 2H), 7.776 (d, J = 8.4 Hz, 1H), 7.966 (d, J 
= 8 Hz, 1H). ESI (+) m/e: 437.21 (M+)(%100), 439.22 
(M++2H)(%95); anal. found: C 60.13, H 3.74, N 6.81, S 
7.43; calcd. for C22H17BrN2OS: C 60.42, H 3.92, N 
6.41, S 7.33. 
 
2-[4-(4-nitrophenylacetamido)benzyl]benzothiazole (6s) 
Yield: 64 %; m.p. = 205–207 ºC; IR v/cm−1: 3254, 1661 
(Amid I), 1598, 1538 (Amid II), 1513, 1455, 1436 
(Amid III), 1347, 970–637, 738–637; 1H NMR (400 
MHz, DMSO-d6) δ/ppm: 3.810 (s, 2H), 4.376 (s, 2H), 
7.303 (d, J = 8.4 Hz, 2H), 7.348 (t, J = 7.2 Hz, J = 6.8 
Hz, 1H), 7.439 (t, J = 6.8 Hz, J = 7.2 Hz, 1H), 7.551–
7.593 (m, 4H), 7.910 (d, J = 8.4 Hz, 1H), 7.959 (d, J = 
8.4 Hz, 1H), 8.170 (d, J = 8.4 2H), 10.291 (s, 1H); ESI 
(+) m/e: 404.32 (M++H)(%100); anal. found: C 65.05, H 
4.39, N 10.50, S 7.88; calcd. for C22H17N3O3S · 0.1 
H2O: C 65.20, H 4.28, N 10.37, S 7.91.  
2-[4-(4-methylphenylacetamido)benzyl]benzothiazole 
(6t) 
Yield 48 %; m.p. = 181–183 ºC; IR v/cm−1: 3284, 3116, 
3045, 2918, 1661 (Amid I), 1596, 1531 (Amid II), 1512, 
1455, 1434 (Amid III), 975–620, 730–620. 1H NMR 
(400 MHz, CDCl3) δ/ppm: 2.340 (s, 3H), 3.658 (s, 2H), 
4.349 (s, 2H), 7.172–7.194 (m, 4H), 7.243 (d, J = 8.4 
Hz, 2H), 7.321 (t, J = 7.2 Hz, J = 8 Hz, 1H), 7.401–
7.462 (m, 4H), 7.766 (d, J = 8 Hz, 1H), 7.964 (d, J = 
8.4 Hz, 1H); ESI (+) m/e: 372.34 (M++H)(%100); anal. 
found: C 74.16, H 5.56, N 7.84, S 8.72; calcd. for 
C23H20N2OS: C 74.16, H 5.41, N 7.52, S 8.61.  
2-[4-(4-methoxyphenylacetamido)benzyl]benzothia- 
zole (6u) 
Yield: 40 %; m.p. = 168–170 ºC. IR v/cm−1: 3293, 3118, 
3039, 2930, 1661 (Amid I), 1598, 1533 (Amid II), 1512, 
1455, 1434 (Amid III), 1249, 1035, 975–620, 730–620. 
1H NMR (400 MHz, CDCl3) δ/ppm: 3.657 (s, 2H), 
3.809 (s, 3H), 4.363 (s, 2H), 6.908 (d, J = 8.4 Hz, 2H), 
7.223 (d, J = 8.8 Hz, 2H), 7.262 (d, J = 8.8 Hz, 2H), 
7.327 (t, J = 7.2 Hz, J = 8.4 Hz, 1H), 7.401–7.462 (m, 
3H), 7.773 (d, J = 7.6 Hz, 1H), 7.969 (d, J = 8.4 Hz, 
1H); ESI (+) m/e: 389.33 (M++H)(%100); anal. found: 
C 70.77, H 5.23, N 7.45, S 8.33; calcd. for 
C23H20N2O2S: C 71.11, H 5.19, N 7.21, S 8.25.  
2-[4-(3-phenylpropanamido)benzyl]benzothiazole (6v) 
Yield: 46 %; m.p. = 163–165 ºC; IR v/cm−1: 3295, 
3188, 3120, 3059, 3028, 2898, 1661 (Amid I), 1600, 
1535 (Amid II), 1511, 1452, 1422 (Amid III), 971–
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609, 730−621. 1H NMR (400 MHz, DMSO-d6) δ/ppm: 
2.620 (t, J = 7.2 Hz, J = 8 Hz, 2H), 2.909 (t, J = 8 Hz, 
J = 7.2 Hz, 2H); 4.401 (s, 2H), 7.177–7.282 (m, 5H), 
7.313 (d, J = 8.4 Hz, 2H), 7.387 (t, J = 7.2 Hz, J = 7.6 
Hz, 1H), 7.481 (t, J = 7.2 Hz, J = 8 Hz, 1H), 7.569 (d, 
J = 8.4 Hz, 2H), 7.948 (d, J = 7.6 Hz, 1H); 8.004 (d, J 
= 8 Hz, 1H) 9.952 (s, 1H); ESI (+) m/e: 379.39 
(M++H)(%100); anal. found: C 74.49, H 5.07, N 7.89, 
S 8.73; calcd. for C23H20N2OS: C 74.16, H 5.41, N 




Yield: 64 %; m.p. = 153–155 ºC; IR v/cm−1: 3303, 3188, 
3120, 3052, 2949, 2897, 1657 (Amid I), 1599, 1534 
(Amid II), 1510, 1454, 1432 (Amid III), 1246, 1034, 
951–612, 730–612. 1H NMR (400 MHz, DMSO-d6): 
2.561 (t, J = 7.2 Hz, J = 8 Hz, 2H), 2.829 (t, J = 8 Hz, J 
= 7.2 Hz, 2H), 3.689 (s, 3H), 4.386 (s, 2H), 6.826 (d, J 
= 8.8 Hz, 2H), 7.143 (d, J = 8.4 Hz, 2H), 7.297 (d, J = 
8.4 Hz, 2H), 7.373 (t, J = 7.2 Hz, J = 7.6 Hz, 1H), 
7.468 (t, J = 7.2 Hz, J = 7.2 Hz, 1H), 7.555 (d, J = 8.4 
Hz, 2H), 7.934 (d, J = 7.6 Hz, 1H), 7.989 (d, J = 7.6 
Hz, 1H), 9.921 (s, 1H). ESI (+) m/e: 403.41 
(M++H)(%100); anal. found: C 71.63, H 5.14, N 7.30, S 





Klebsiella pneumoniae isolate, which has an extended 
spectrum beta lactamase enzyme (ESBL), Pseudomonas 
aeruginosa isolate (gentamicin-resistant), Escherichia 
coli isolate , which has an extended spectrum beta lac-
tamase enzyme (ESBL), Bacillus subtilis isolate (re-
sistant to ceftriaxon), Staphylococcus aureus isolate 
[meticilline-resistant (MRSA)], K. pneumoniae RSKK 
574 (Refik Saydam National Public Health Agency 
Culture Collection), P. aeruginosa ATCC 25853 
(American Type Culture Collection), E. coli ATCC 
25922, B. subtilis ATCC 6633, S. aureus ATCC 25923, 
Candida albicans ATCC 10231. 
 
Methods 
Standard strains of K. pneumoniae RSKK 574, P. 
aeruginosa ATCC 25853, E. coli ATCC 25922, B. 
subtilis ATCC 6633, S. aureus ATCC 25923, C. 
albicans ATCC 10231 and clinical isolates of these 
microorganisms resistant to various antimicrobial 
agents were included in the study. Resistance was 
determined by Kirby Bauer Disk Diffusion method 
according to the guidelines of Clinical and Laboratory 
Standards Institute (CLSI)27 in the clinical isolates. 
Standard powders of ampicillin trihydrate, gen-
tamycin sulphate, rifampicin, ofloxacin, fluconazole 
and amphotericin B were obtained from the manufac-
turers. Stock solutions were dissolved in dimethyl-
sulphoxide (ofloxacin), pH 8 phosphate buffer saline 
(PBS) (ampicilin trihydrate) methanol (rifampicin) and 
distilled water (gentamicin sulfate, fluconazole and 
amphotericin B). Newly (6a–6w) and previously (7a–
7k) synthesized compounds were dissolved in 80 % 
DMSO-20 % EtOH. 
Bacterial isolates were subcultured in Mueller 
Hinton Agar (MHA) plates and incubated over night at 
37 oC and C. albicans was subcultured in Sabouraud 
Dextrose Agar (SDA) plates at 35 oC for 24–48 h. The 
microorganisms were passaged at least twice to ensure 
purity and viability. 
The solution of the newly (6a–6w) and previous-
ly (7a–7k) synthesized compounds and standard drugs 
were prepared at 400, 200, 100, 50, 25, 12.5, 6.25, 
3.125, 1.562, 0.78, 0.39, 0.19, 0.095, 0.047, 0.024 
µg/ml concentrations, in the wells of microplates by 
diluting in Mueller Hinton Broth (MHB). 
Bacterial susceptibility testing was performed 
according to the guidelines of CLSI M100-S16.28 The 
bacterial suspensions used for inoculation were pre-
pared at 105 cfu/ml by diluting fresh cultures at 
MacFarland 0.5 density (107 cfu/ml). Suspensions of 
the bacteria at 105 cfu/ml concentration were inoculat-
ed to the twofold diluted solution of the compounds. 
There were 104 cfu/ml bacteria in the wells after in-
oculations. MHB was used for diluting the bacterial 
suspension and for twofold dilution of the compound. 
80 % DMSO-20 % EtOH, methanol, DMSO, PBS, 
pure microorganisms and pure media were used as 
control wells. A 10 µl bacteria inoculum was added to 
each well of the microdilution trays. The trays were 
incubated at 37 oC and MIC endpoints were read after 
24 h of incubation. 
C. albicans was subcultured in SDA plates, and 
incubated at 35 oC for 24–48 h prior to antifungal sus-
ceptibility testing. Susceptibility testing was performed 
in RPMI-1640 medium with L-glutamine buffered pH 
7 with 3-[N-morpholino]-propansulfonic acid (MOPS) 
and culture suspensions were prepared through the 
guideline of CLSI M27-A3.29 Yeast suspensions were 
prepared according to McFarland 0.5 density and a 
working suspension was made by a 1:100 dilution 
followed by a 1:20 dilution of the stock suspension 
(2.5×103 CFU/ml). A 10 µl yeast inoculum was added 
to each well of the microdilution trays. The trays were 
incubated at 35 oC and MIC end points were read after 
48 h of incubation. 
All organisms were tested in triplicate in each 
run of the experiments. The lowest concentration of 
the compound that completely inhibits macroscopic 
growth was determined and minimum inhibitory con-
centrations (MICs) were reported in Table 1. 
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no X Y R K.p. K.p.* P.a P.a.* E.c. E.c.* B.s. B.s.* S.a. S.a.* C.a. 
6a - - H 25 50 25 25 25 50 25 50 50 25 25 
6b - - OCH(CH3)C2H5 12.5 50 50 25 50 50 200 100 50 25 25 
6c - CH2 H 25 50 50 25 50 25 200 50 50 25 25 
6d - CH2 NO2 25 25 12.5 25 12.5 50 25 50 50 12.5 25 
6e - C2H4 H 25 25 25 6.25 25 12.5 25 50 50 12.5 25 
6f - C2H4 OCH3 25 12.5 50 12.5 25 25 200 50 25 12.5 25 
6g CH2 - H 50 50 50 25 50 50 200 50 100 25 25 
6h CH2 - F 50 50 50 25 50 50 50 100 50 25 25 
6i CH2 - Cl 50 50 50 50 50 50 50 50 25 25 25 
6j CH2 - Br 25 12.5 12.5 25 12.5 25 25 12.5 6.25 12.5 25 
6k CH2 - NO2 50 50 50 25 50 50 50 50 100 25 25 
6l CH2 - C2H5 50 50 50 50 50 50 200 25 50 25 25 
6m CH2 - C(CH3)3 50 50 50 50 50 50 50 50 50 25 25 
6n CH2 - OCH(CH3)C2H5 50 50 50 50 50 50 200 100 50 25 25 
6o CH2 CH2 H 50 50 25 25 50 50 50 50 50 25 25 
6p CH2 CH2 F 50 50 50 50 50 50 50 50 100 25 50 
6q CH2 CH2 Cl 25 50 50 25 25 50 50 25 50 25 25 
6r CH2 CH2 Br 50 50 50 50 50 50 25 50 50 25 25 
6s CH2 CH2 NO2 50 50 50 25 50 50 50 50 50 25 25 
6t CH2 CH2 CH3 25 25 12.5 25 50 12.5 25 25 25 12.5 25 
6u CH2 CH2 OCH3 50 50 25 25 50 50 50 50 50 25 25 
6v CH2 C2H4 H 50 25 50 50 50 50 50 50 100 25 25 
6w CH2 C2H4 OCH3 25 50 50 25 25 50 50 50 50 25 25 
7a - - F 25 50 25 25 50 50 50 50 50 25 25 
7b - - Cl 50 25 25 25 50 50 50 50 50 12.5 25 
7c - - Br 50 50 25 25 50 50 50 100 50 25 25 
7d - - C2H5 25 50 25 25 25 50 50 50 50 6.25 12.5 
7e - - C(CH3)3 25 50 25 25 25 50 50 100 50 12.5 12.5 
7f - - NO2 50 50 25 25 25 50 50 50 50 12.5 12.5 
7g - CH2 F 50 50 25 25 25 50 50 25 100 50 25 
7h - CH2 Cl 50 50 25 25 50 50 50 50 50 50 25 
7i - CH2 Br 50 50 12.5 25 25 50 50 50 50 25 12.5 
7j - CH2 CH3 25 50 25 25 50 50 50 50 50 25 25 
7k - CH2 OCH3 12.5 50 25 6.25 12.5 25 12.5 50 50 12.5 12.5 
Ampicillin trihydrate - - - - 3.125 400 0.78 0.78 0.78 - - 
Gentamycin sulfate 0.39 6.25 1.562 50 0.78 12.5 0.39 0.19 0.78 6.25 - 
Rifampicin - - - - - - 0.19 3.125 0.0225 1.562 - 
Ofloxacin 0.19 3.125 6.25 50 0.19 6.25 0.19 3.125 0.19 1.562 - 
Fluconazol - - - - - - - - - - 0.78 
Amphotericin B - - - - - - - - - - 0.78 
Abbrevations: MIC: Minimum Inhibitory Concentration, K.p.: Klebsiella pneumoniae RSKK 574, K.p.*: K. pneumoniae isolate, 
P.a.: Pseudomonas aeruginosa ATCC 25853, P.a.*: P. aeruginosa isolate, E.c.: Escherichia coli ATCC 25922, E.c.*: E. coli 
isolate, B.s.: Bacillus subtilis ATCC 6633, B.s.*: B. subtilis isolate, S.a.: Staphylococcus aureus ATCC 25923, S.a.*: S. aureus 
isolate, C.a.: Candida albicans ATCC 10231. 
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RESULTS AND DISCUSSION 
Chemistry 
The synthetic pathways for preparation of the target 
compounds listed in Table 1 are shown in Scheme 1 and 
Scheme 2. The final compounds were easily obtained in 
two steps. In the first, 2-(4-aminobenzyl/phenyl)benzo-
thiazole as a starting material was performed by con-
densing of appropriate aminophenols and suitable acids 
in polyphoshoric acid (Scheme 1). In the second reac-
tion, an amidification was done. For this reaction, 2-(4-
aminobenzyl/phenyl)benzothiazole was treated with 
suitable carboxylic chloride obtained by using suitable 
carboxylic acid with thionyl chloride to get compounds 
6a–6w as given in Scheme 2. The structures were sup-
ported by spectral data. The IR, 1H NMR, Mass spectra 
and Elemental Analysis results are in agreement with 
the proposed structures. Physical and spectral data of 
the compounds are reported in Table 1. All of the com-
pounds (6b–6w) are original except 6a.23 
According to the spectroscopic data of the final 
compounds the IR showed characteristic C=O (amide) 
stretching bands in the 1644–1670 cm−1 region. In the 
1H NMR spectra of the compounds 6a–6w, the signal of 
NH proton was observed at 10.722–9.921 ppm as a 
singlet band; CH2 protons between phenyl and ben-
zothiazole ring were observed at 4.372–4.426 ppm as a 
singlet band for compounds 6g–6w. CH2 protons were 
observed at 3.810–3.658 ppm as a singlet band for com-
pounds which carries phenylacetylamido moiety (6c–
6d, 6o–6t). -COCH2CH2 protons were observed at 
2.927–2.543 ppm as triplet bands for compounds 6e,6f, 
6v,6w. Besides, all the aromatic protons were observed 
at the expected regions. On the other hand, MASS spec-
tra of the compounds showed M+H peaks, since the 
electrospray ionization method was employed, in accor-




All the newly (6a–6w) and previously (7a–7k) synthe-
sized 2-[4-(4-substitutedbenzamido / phenylacetamido 
/ phenylpropionamido) benzyl / phenyl]benzothiazole 
derivatives were in vitro tested for antibacterial activi-
ty against K. pneumoniae RSKK 574, P. aeruginosa 
ATCC 25853, E. coli ATCC 25922, K. pneumoniae 
isolate, which has an extended spectrum beta lactama-
se enzyme (ESBL), E. coli isolate (ESBL), P. aeru-
ginosa isolate (gentamicin-resistant) as Gram-negative 
bacteria, B. subtilis ATCC 6633, S. aureus ATCC 
25923, B. subtilis isolate (resistant to ceftriaxon), S. 
aureus isolate (meticilline-resistant (MRSA)) as Gram-
positive bacteria and the antifungal activity was evalu-
ated against C. albicans ATCC 10231. The standard 
agents, ampicillin trihydrate, gentamycin sulfate, ri-
fampicin and ofloxacin for antibacterial activity and 
fluconazole and amphotericin B for antifungal activity 
were also screened under identical conditions for qual-
ity control and comparison. The MIC values were 
determined by microdilution method according to the 
guidelines of Clinical and Laboratory Standards Insti-
tute (CLSI).28,29 
The observed in vitro antimicrobial activity re-
sults of the tested compounds were given in Table 1. 
The synthesized compounds were found showing an 
antibacterial activity at MIC values between 6.25–50 
μg/ml for Gram-negative bacteria. Among the tested 
compounds, 2-[4-(phenylpropionamido)phenyl]benzo-
thiazole (6e) and 2-[4-(4-methoxyphenylacetami-
do)phenyl]benzothiazole (7k) were found the most 
potent derivative at a MIC value of 6.25 µg/ml against 
the screened drug-resistant enteric Gram-negative rod 
P.aeruginosa isolate providing three folds higher 
potency than the compared standard drugs; gentamy-
cin sulfate and ofloxacin. On the other hand, 6f 
showed also good activity at a MIC value of 12.5 
µg/ml against the same microorganism. It revealed 
that the compound having phenyl acetamide moiety 
by holding a methoxy group on position R (6f, 7k) 
was performed one or two folds better activity against 
drug-resistant P. aeruginosa isolate than the other 
tested compounds. On the other hand, when CH2 
group as a bridge between benzothiazole and phenyl 
came the activity against P. aeruginosa isolate pretty 
decreased as seen in Table 1 (compounds 6e and 6f 
compared to compounds 6v and 6w). This means that 
planarity between phenyl on second position of 
benzothiazole and bicyclic structure is very important 
for potent antimicrobial activity against drug-resistant 
enteric Gram-negative rod P.aeruginosa. Among the 
tested compounds 6f and 6j are the most active with a 
MIC value of 12.5 μg/ml against drug-resistant K. 
pneumoniae. Only compounds 6e and 6t showed the 
same activity compared to standard drug Gentamycine 
sulfate against drug-resistant Gram-negative bacteria 
E.coli. 
According to Table 1, the synthesized compounds 
showed a broad spectrum of activity with MIC values 
200–6.25 µg/ml against some Gram-positive bacteria 
such as S. aureus, B. subtilis and their drug resistant 
isolates. All the tested compounds indicated a moderate 
activity against B. subtilis. In addition, most of the com-
pounds were found as showing one or two folds dilu-
tions more antibacterial active against the screened drug 
resistant S. aureus isolate compared to the nonresistant 
S. aureus ATCC 25923 strain. The compound, 2-[4-(4-
ethylbenzamido)phenyl]benzothiazole (7d), indicated 
the most potent inhibitory effect against the drug re-
sistant S. aureus isolate with 6.25 μg/ml MIC value 
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showing as the same activity compared to gentamycin 
sulfate. The derivative, 6j showed more potent inhibito-
ry effect with a MIC value of 6.25 μg/ml than the other 
compounds against S. aureus. 
Moreover, most of the synthesized compounds 
exhibited a moderate antifungal activity for C. albicans 
with MIC values between 12.5–25 μg/ml except 6p. It 
can be concluded that the compound is holding a fluo-
rine atom on position R of phenyl ring at 
phenylacetamido moiety instead of benzamido play a 




Because of the need of new antibacterial drugs active 
against the multi-drug resistance bacteria, herein, we 
synthesized 2-[4-(4-substitutedbenzamido / phenyla-
cetamido / phenylpropionamido) benzyl / phenyl]benzo-
thiazole derivatives (6a–6w) as a new antimicrobial 
agents in order to be able to contribute to the antimicro-
bial researchers. 
In according to our present study, it can be pro-
posed, that 2-phenylbenzothiazole moiety was found to 
be more important than 2-benzylbenzothiazole for en-
hancing potency against Gram-negative bacteria espe-
cially the drug-resistant P. aeruginosa isolate. Further-
more, benzamide moiety at position 2 of benzothiazole 
ring was more important for increasing potency against 
the Gram-positive S. aureus. 
These observations provide some predictions in 
order to design further antimicrobial active compounds 
prior to their synthesis following with QSAR and mo-
lecular modelling studies. 
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